Loading...
•
Dec 31, 2019
Avadel Q4 2019 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2019.
Key Takeaways
Avadel Pharmaceuticals reported fourth-quarter revenues of $11.0 million, a decrease compared to $20.9 million in the fourth quarter of 2018. The net loss for the quarter was $2.7 million, or $0.07 per share, compared to a net loss of $63.9 million, or $1.72 per share, for the same period in 2018. The company's cash, cash equivalents, and marketable securities totaled $64.2 million as of December 31, 2019.
Revenues for the fourth quarter of 2019 were $11.0 million, compared to $20.9 million in the fourth quarter of 2018.
R&D expenses were $7.8 million in the fourth quarter of 2019, compared to $6.1 million in the fourth quarter of 2018.
SG&A expenses were $7.7 million in the fourth quarter of 2019, compared to $23.2 million in the fourth quarter of 2018.
Net loss for the fourth quarter of 2019 was $2.7 million, or $0.07 per share, compared to a net loss of $63.9 million or $1.72 per share for the same period in 2018.
Forward Guidance
Revenue for the first quarter of 2020 is expected to be at or above $10 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...